ú9bn Glaxo bid gets the green flag

Glaxo’s ú9bn bid for Wellcome is believed to have been cleared by the European Commission. The decision, taken by the EC’s merger task force, is the first legal hoop the controversial bid has to jump through.

Glaxo’s ú9bn bid for Wellcome is believed to have been cleared by the European Commission.

The decision, taken by the EC’s merger task force, is the first legal hoop the controversial bid has to jump through. A merger referral would have delayed and possibly killed the takeover.

But it is understood that the committee met in Brussels on Tuesday to agree to accept Glaxo’s proposals. The deal still faces anti-trust clearance in the US.

It is understood that the EC will ask Glaxo to licence existing or future anti-migraine drugs, including Imigran, to a third party to ensure continuing competition in the market. Wellcome is preparing a similar drug 311C which sparked fears that Glaxo would hold a dominant position in the market.

Comments

    Leave a comment

    Close

    Discover even more as a subscriber

    This article is available for subscribers only.

    Sign up now for your access-all-areas pass.

    Subscribers get unlimited access to unrivalled coverage of the biggest issues in marketing and world-renowned columnists, alongside carefully curated reports and briefings from Econsultancy. Find out more.

    If you are an existing print subscriber find out how you can get access here.

    Subscribe now

    Got a question?

    Contact us on +44 (0)20 7292 3703 or email customerservices@marketingweek.com

    If you are looking for our Jobs site, please click here

    Subscribers get unlimited access to unrivalled coverage of the biggest issues in marketing and world-renowned columnists, alongside carefully curated reports and briefings from Econsultancy. Find out more.

    If you are an existing print subscriber find out how you can get access here.

    Subscribe now